David A. Siegel Biotechnology

Two Sigma Advisers, LP

$42.8 Billion
Q1 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
REGN Regeneron Pharmaceuticals, Inc.	$60.4B	$351 Million 0.82% of portfolio	553,800	Q1 2025 New
NVO Novo Nordisk A S	$162B	$337 Million 0.79% of portfolio	4,856,800	Q1 2025 Added 375.36%
MRNA Moderna, Inc.	$13.4B	$108 Million 0.25% of portfolio	3,808,500	Q1 2025 Added 3,572.61%
RPRX Royalty Pharma PLC	$16B	$90.4 Million 0.21% of portfolio	2,903,900	Q1 2025 Reduced 20.94%
EXEL Exelixis, Inc.	$14.7B	$84.4 Million 0.2% of portfolio	2,285,090	Q1 2025 Added 40.37%
ALNY Alnylam Pharmaceuticals, Inc.	$40.5B	$74.5 Million 0.17% of portfolio	275,800	Q1 2025 Added 250.0%
IONS Ionis Pharmaceuticals Inc	$6B	$63.1 Million 0.15% of portfolio	2,092,011	Q1 2025 Added 55.05%
ADMA Adma Biologics, Inc.	$3.54B	$51.3 Million 0.12% of portfolio	2,586,600	Q1 2025 Reduced 12.32%
GMAB Genmab A/S	$15.4B	$38.6 Million 0.09% of portfolio	1,973,700	Q1 2025 Added 19.36%
CORT Corcept Therapeutics Inc	$7.31B	$35 Million 0.08% of portfolio	306,800	Q1 2025 Reduced 19.64%
RARE Ultragenyx Pharmaceutical Inc.	$1.91B	$33.9 Million 0.08% of portfolio	937,200	Q1 2025 Added 2.59%
BMRN Biomarin Pharmaceutical Inc	$11B	$33 Million 0.08% of portfolio	467,314	Q1 2025 Added 336.68%
CRSP Crispr Therapeutics Ag	$5.05B	$27.1 Million 0.06% of portfolio	797,200	Q1 2025 Added 840.09%
BCRX Biocryst Pharmaceuticals Inc	$1.59B	$24.2 Million 0.06% of portfolio	3,220,712	Q1 2025 Added 28.84%
MRUS Merus N.V.	$3.07B	$23.3 Million 0.05% of portfolio	554,400	Q1 2025 Reduced 23.09%
MNKD Mannkind Corp	$1.04B	$18.8 Million 0.04% of portfolio	3,735,627	Q1 2025 Added 20.79%
HALO Halozyme Therapeutics, Inc.	$8.11B	$18.7 Million 0.04% of portfolio	293,729	Q1 2025 Added 4,878.46%
TVTX Travere Therapeutics, Inc.	$983M	$18.7 Million 0.04% of portfolio	1,045,700	Q1 2025 Added 8.08%
ARGX Argenx Se	$32.8B	$17.9 Million 0.04% of portfolio	30,200	Q1 2025 New
SRPT Sarepta Therapeutics, Inc.	$1.04B	$17.6 Million 0.04% of portfolio	276,334	Q1 2025 New
AXSM Axsome Therapeutics, Inc.	$4.32B	$17.4 Million 0.04% of portfolio	149,600	Q1 2025 Added 2,274.6%
LEGN Legend Biotech Corp	$7.26B	$17.1 Million 0.04% of portfolio	504,100	Q1 2025 Added 53.97%
ACAD Acadia Pharmaceuticals Inc	$3.76B	$16.1 Million 0.04% of portfolio	967,500	Q1 2025 Reduced 23.41%
IMCR Immunocore Holdings PLC	$1.54B	$15.5 Million 0.04% of portfolio	523,400	Q1 2025 Reduced 13.47%
BGNE Bei Gene, Ltd.	$23.5B	$14.1 Million 0.03% of portfolio	62,400	Q1 2025 New
NTLA Intellia Therapeutics, Inc.	$1.03B	$14.1 Million 0.03% of portfolio	1,982,317	Q1 2025 Reduced 0.8%
JAZZ Jazz Pharmaceuticals PLC	$7.41B	$12.2 Million 0.03% of portfolio	98,200	Q1 2025 Added 20.2%
INSM Insmed Inc	$14.1B	$12 Million 0.03% of portfolio	157,200	Q1 2025 Reduced 51.85%
AMRN Amarin Corp Plcuk	$6.21B	$11.6 Million 0.03% of portfolio	1,293,200	Q1 2025 Reduced 25.65%
INVA Innoviva, Inc.	$1.3B	$10.4 Million 0.02% of portfolio	571,500	Q1 2025 Added 179.46%
XENE Xenon Pharmaceuticals Inc.	$1.89B	$10 Million 0.02% of portfolio	298,800	Q1 2025 Added 0.03%
PTCT Ptc Therapeutics, Inc.	$3.2B	$9.65 Million 0.02% of portfolio	189,442	Q1 2025 Reduced 47.44%
BBIO Bridge Bio Pharma, Inc.	$6.86B	$9.44 Million 0.02% of portfolio	273,155	Q1 2025 New
MIRM Mirum Pharmaceuticals, Inc.	$1.9B	$9.31 Million 0.02% of portfolio	206,600	Q1 2025 Added 18.46%
ARWR Arrowhead Pharmaceuticals, Inc.	$1.67B	$9.22 Million 0.02% of portfolio	723,800	Q1 2025 Added 68.05%
FOLD Amicus Therapeutics, Inc.	$1.7B	$8.43 Million 0.02% of portfolio	1,033,276	Q1 2025 Added 822.77%
NUVL Nuvalent, Inc.	$3.5B	$7.18 Million 0.02% of portfolio	101,300	Q1 2025 Reduced 27.69%
QURE Uni Qure N.V.	$706M	$7.09 Million 0.02% of portfolio	668,494	Q1 2025 Reduced 11.68%
IDYA Ideaya Biosciences, Inc.	$1.18B	$6.77 Million 0.02% of portfolio	413,600	Q1 2025 Reduced 10.2%
SNDX Syndax Pharmaceuticals Inc	$545M	$6.18 Million 0.01% of portfolio	503,152	Q1 2025 Reduced 6.12%
ABCL Ab Cellera Biologics Inc.	$1.46B	$5.9 Million 0.01% of portfolio	2,644,800	Q1 2025 Added 1.4%
TGTX Tg Therapeutics, Inc.	$5.36B	$5.22 Million 0.01% of portfolio	132,400	Q1 2025 Added 1,137.38%
XERS Xeris Biopharma Holdings, Inc.	$683M	$5.08 Million 0.01% of portfolio	925,615	Q1 2025 Added 6,636.15%
KYMR Kymera Therapeutics, Inc.	$2.5B	$5.02 Million 0.01% of portfolio	183,300	Q1 2025 Reduced 29.58%
MRVI Maravai Lifesciences Holdings, Inc.	$354M	$4.95 Million 0.01% of portfolio	2,238,000	Q1 2025 Added 933.72%
HRMY Harmony Biosciences Holdings, Inc.	$2.22B	$4.67 Million 0.01% of portfolio	140,800	Q1 2025 Added 42.37%
AVXL Anavex Life Sciences Corp.	$945M	$4.36 Million 0.01% of portfolio	508,200	Q1 2025 Added 3.59%
LQDA Liquidia Corp	$1.26B	$4.25 Million 0.01% of portfolio	287,800	Q1 2025 Added 58.31%
XNCR Xencor Inc	$552M	$4.24 Million 0.01% of portfolio	398,300	Q1 2025 Reduced 9.89%
APLS Apellis Pharmaceuticals, Inc.	$2.15B	$4.19 Million 0.01% of portfolio	191,800	Q1 2025 New

Shares Options

David A. Siegel

David A. Siegel is the co-founder and CEO of Two Sigma Advisers, a successful investment firm that uses technology and data-driven approaches to investing. Siegel is known for his expertise in quantitative investing and his innovative approach to investing. He has generated strong returns for his clients over the long term.

Track David A. Siegel's portfolio

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account